02132nas a2200265 4500008004100000022001400041245014200055210006900197260009700266300001200363490000600375520116200381653000901543653001301552653001301565653002501578653001401603653001801617100001901635700001801654700002101672700002601693700001901719856012801738 2015 eng d a2210-803300aLannea coromandelica attenuates glucagon and oxyntomodulin mediated cAMP formation in HEK cells stably-expressing human glucagon receptor0 aLannea coromandelica attenuates glucagon and oxyntomodulin media aOFFICE JENA, P O BOX 100537, 07705 JENA, GERMANYbELSEVIER GMBH, URBAN & FISCHER VERLAGcSEP a153-1570 v53 a

Antagonism of glucagon is a potential therapeutic approach for Type 2 diabetes mellitus (T2DM). The bark extract of Lannea coromandelica has been reported to have hypoglycemic or anti-diabetic effects on animal models and human subjects. The aim of this study was to elucidate the molecular mechanisms of L. coromandelica extract as a glucagon receptor antagonist. The aqueous extract of L. coromandelica bark attenuated glucagon-mediated cAMP formation in a concentration dependent manner with an IC50 value of 4.24 +/- 1.31 mu g/ml. It shifted a concentration response curve of glucagon towards the right with a 4, 21 and 40-fold change in IC50 at 6.25, 12.5 and 25 mu g/ml of extract, respectively. Additionally, it attenuated an oxyntomodulin-mediated cAMP response. The extract was found specifically to inhibit glucagon mediated cAMP formation since it was ineffective in reducing cAMP levels nonspecifically-elevated by forskolin. The data support that the aqueous extract of L. coromandelica antagonizes the glucagon receptor and has the potential to reduce glucagon mediated liver glucose output. (C) 2015 Elsevier GmbH. All rights reserved.

10acAMP10aDiabetes10aGlucagon10aLannea coromandelica10aMechanism10aOxyntomodulin1 aWalunj, Sameer1 aGupta, Rajesh1 aJoshi, Swati, P.1 aSabharwal, Sushma, G.1 aJoshi, Kalpana uhttps://library.ncl.res.in/content/lannea-coromandelica-attenuates-glucagon-and-oxyntomodulin-mediated-camp-formation-hek-002239nas a2200241 4500008004100000022001400041245017700055210006900232260000800301300001100309490000800320520138100328653001501709653001701724653000801741653001601749653002001765100002101785700001901806700001901825700002101844856013201865 2020 eng d a0960-076000a6 alpha-Hydroxy-4[14], 10[15]-guainadien-8 beta, 12-olide induced cell cycle arrest via modulation of EMT and Wnt/beta-catenin pathway in HER-2 positive breast cancer cells0 a6 alphaHydroxy414 1015guainadien8 beta 12olide induced cell cycl cMAR a1055140 v1973 a

Cyathocline purpurea has potential biological activities and has been widely used in traditional Chinese and Ayurvedic medicine. The aim of the present study is to elucidate the anticancer effect of its 6 alpha-hydroxy-4[14], 10 [15]-guainadien-8 beta, 12-olide (SRCP1) against HER-2 positive subtype of breast carcinoma. Anticancer effect of SRCP1 was assessed by cell viability, senescence, apoptosis, cell cycle, DNA synthesis, and gene expression assays. The activity was further validated by the molecular docking study. SRCP1 inhibits human HER-2 positive breast cancer growth via inhibition of DNA synthesis in a dose-dependent manner. SRCP1 induces cell cycle arrest at G(2)/M phase, late apoptosis, and necrosis. Further, it induces senescence causing reduction in migration via down-regulation of EMT. A remarkable increase in the number of necrotic cells and Annexin-V staining revealed that exposure to SRCP1 triggers late apoptosis. Treatment with SRCP1 increased E-cadherin, p21, p53, ER-alpha expression and decreased beta-catenin, MMP-9, snaill, TNF-alpha expression. SRCP1 showed binding affinity towards an active site of the HER-2 receptor. Our results of molecular docking and biological assays demonstrated the potent anticancer activity of SRCP1 in MDA-MB-453 cells via multiple pathways including EMT, TNF-alpha, and Wnt/beta-catenin signaling.

10aAnticancer10abeta-Catenin10aEMT10aGuaianolide10aHER-2 inhibitor1 aJavir, Gitanjali1 aJoshi, Kalpana1 aKhedkar, Vijay1 aRojatkar, Supada uhttps://library.ncl.res.in/content/6-alpha-hydroxy-414-1015-guainadien-8-beta-12-olide-induced-cell-cycle-arrest-modulation-emt07987nas a2200157 4500008004100000245011600041210006900157260000800226300001100234490000700245520739300252100001907645700001907664700001707683856012907700 2022 eng d00aComparison of hydrodynamic characteristics of Tulsion and Siran immobilised beads in a fluidised bed bioreactor0 aComparison of hydrodynamic characteristics of Tulsion and Siran  cAUG a1024280 v433 a

The fluidised bed reactors are successfully utilised in various bioprocesses to produce high value products using immobilised cells and enzymes. The present work aims at evaluating hydrodynamic characteristics of a three phase fluidised bed bioreactor using Tulsion® A-1X MP, Tulsion® ADS-400 and Tulsion® ADS-800, polystyrene and polyacrylic based three types of free and immobilised cells solid carriers viz. and comparing their performance with Siran® SIKUG41 glass beads. The hydrodynamic parameters such as particle density (cells and beads), drag coefficient, minimum and maximum fluidisation velocity, particle settling velocity were estimated and compared in water and biological media (E2 and MSM) having varying rheological properties. The relationships between drag coefficient (CD)–Reynolds numbers (NRe), superficial liquid velocity (Uf)–void fraction(ε), expansion index(n)–NRe were obtained.

1 aKashid, Shweta1 aJoshi, Kalpana1 aNene, Sanjay uhttps://library.ncl.res.in/content/comparison-hydrodynamic-characteristics-tulsion-and-siran-immobilised-beads-fluidised-bed